Not Yet RecruitingPhase 2ACTRN12605000707662

A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study Of Ularitide In The Treatment Of Subjects With Acute Decompensated Heart Failure

Sponsor

Protein Design Labs, Inc.

Enrollment

200 participants

Start Date

Jan 1, 2006

Study Type

Interventional

Conditions

Acute Decompensated Heart Failure

Summary

Nepean Hospital Derby Street Penrith NSW 2751 ethics submission due on 12th Oct 05. Royal Adelaide Hospital Level 6, Outpatients Building North Terrace, SA 5000 ethics submission 19th Oct 05

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests ularitide, an IV medication, for treating acute decompensated heart failure (a sudden worsening of heart failure symptoms). Adults aged 18 and older who are hospitalized for acute heart failure may be eligible. Participants would receive either ularitide or a placebo through an IV while being monitored in a hospital bed.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This is a randomized, 2-arm study in which ularitide (15 ng/kg/min) or placebo will be administered IV continuously over 24 hours, in addition to standard therapy. Subjects must receive the dose of s

This is a randomized, 2-arm study in which ularitide (15 ng/kg/min) or placebo will be administered IV continuously over 24 hours, in addition to standard therapy. Subjects must receive the dose of study drug within one hour after randomization.